中文摘要
申请人主要从事RNA病毒的反向遗传学、病毒的生物矿化等前沿交叉技术研究,在病毒工程领域取得一系列原创性成果,主要包括:1)建立了主要虫媒黄病毒的反向遗传学技术平台,发现多个关键毒力位点与RNA调控元件;2)提出了病毒生物矿化的科学概念,成功实现了病毒的壳工程修饰,可有效提高疫苗热稳定;3)提出了基于黄病毒基因组甲基化修饰的靶向减毒策略,揭示其逃避宿主天然免疫识别的新机制。在国家自然科学基金5项课题等资助下,先后以通讯作者、并列通讯作者在PNAS、J Virol、Angew Chem等发表SCI论文68篇,累计影响因子>280,累计被引>600次,出版专(译)著3部,申请发表专利26项,已授权8项。兼任中国微生物学会病毒学青委会副主委,Sci Rep、BMC Infect Dis等国际期刊编委,获总后勤部科技新星、北京市科技新星、梅里埃优秀青年科学家奖。
英文摘要
Dr. Cheng-Feng Qin's primary research focuses on virus genetic engineering and shell engineering by using reverse genetic technology and biomineralization strategy. As corresponding or co-corresponding author, Cheng-Feng has published 68 peer-reviewed papers in SCI-indexed journals including PNAS, ACS Nano, Plos Pathogens, J Virol, Angew Chem, etc. The total impact factor is >280 with more than 600 citations. He served as Deputy Director of Young Virology Committee, Chinese Society of Microbiology, Associate Editor of BMC Infectious Diseases and Editorial Board member of Scientific Reports, BioMed Research International, etc. Dr Qin has been supported by 5 grants from NSFC, awarded as S&T Nova by General Logistics Department and Beijing City. Dr. Qin has published three books in Chinese, and now holds 8 patents with 26 patents under evaluation. His major scientific contributions include: 1) He developed the reverse genetic system of mosquito-borne flavirviruses that are threating China, by which rational engineered viruses could be created, and a novel cis-acting RNA element DCS-PK within the coding region of flavivirus genome and a panel of virulence determinants were firstly identified; 2) He proposed the concept of virus shell engineering, by which the physical, chemical and biological properties of infectious virus particles could be well controlled due to inorganic mineral shell, and shell engineering of viral vaccines with inorganic mineral was shown to improve vaccine thermal stability; 3) He demonstrated the potential of a novel attenuation strategy targeting at viral methyltransferase, and a series of recombinant flavivirus vaccine candidates that are highly sensitive to host IFN system are rationally designed and developed.
